Mitochondria-Targeting Peptide SS-31 Dramatically Improves Pulmonary Hypertension in Mice
The mitochondria-targeting peptide SS-31 improved virtually every aspect of pulmonary arterial hypertension in mice — from blood pressure to fibrosis to DNA damage — by protecting cells at the mitochondrial level.
Quick Facts
What This Study Found
The mitochondria-targeting antioxidant peptide SS-31 (2 mg/day IP for 60 days) significantly reduced right ventricular systolic blood pressure and lung injury in mice with TAC-induced pulmonary arterial hypertension. SS-31 simultaneously improved multiple disease pathways: it decreased oxidative stress (NOX-1/NOX-2), inflammation (MMP-9/TNF-α/iNOS), calcium overload (TRPC channels), apoptosis (BAX/caspase 3/PARP), fibrosis (Smad3/TGF-β), hypoxia signaling (HIF-1α), and DNA damage (γ-H2AX).
Conversely, SS-31 increased antioxidant proteins (HO-1/NQO-1/GR/GPx), anti-fibrotic markers (Smad1/5, BMP-2), small vessel number, and alveolar sacs — demonstrating comprehensive protection of lung tissue architecture and function.
Key Numbers
2 mg/day × 60 days · RVSBP significantly reduced · 8+ pathological pathways improved · Antioxidant proteins increased · Lung injury score improved · Muscularized vessels reduced
How They Did This
Adult male C57BL mice were divided into three groups: sham-operated controls, TAC-induced PAH, and TAC+SS-31 (2 mg/day intraperitoneal for 60 days). Right ventricular systolic blood pressure was measured on day 60. Heart and lung tissues were analyzed for oxidative stress, inflammation, calcium overload, apoptosis, fibrosis, hypoxia, DNA damage, and endothelial function markers via histological and biochemical examination.
Why This Research Matters
Pulmonary arterial hypertension has limited treatment options and carries a poor prognosis. SS-31 (also known as elamipretide/Bendavia) is a remarkable peptide that selectively targets the inner mitochondrial membrane, protecting cells from oxidative damage at its source. This study shows SS-31 improves virtually every aspect of PAH pathology — from blood pressure to fibrosis to DNA damage — suggesting that mitochondrial dysfunction is a central driver of PAH and that targeting it with this peptide addresses the root cause rather than just symptoms.
The Bigger Picture
SS-31 (elamipretide) is one of the most-studied mitochondria-targeting peptides, with clinical trials for heart failure and other conditions. This study adds pulmonary hypertension to its potential therapeutic portfolio and supports the broader concept that mitochondrial dysfunction underlies many cardiovascular diseases. If these results translate to humans, SS-31 could offer a fundamentally different approach to treating PAH — protecting mitochondria rather than just dilating blood vessels.
What This Study Doesn't Tell Us
This is a mouse model study using TAC-induced PAH, which may not fully replicate the complex pathophysiology of human pulmonary hypertension. Only one dose of SS-31 was tested, so the optimal therapeutic dose is unknown. The 60-day treatment period is relatively short for a chronic disease. The mechanisms were characterized descriptively (biomarker changes) without detailed pathway analysis to determine which effects are primary versus secondary to mitochondrial protection.
Questions This Raises
- ?Can SS-31’s benefits in mouse PAH be replicated in human pulmonary hypertension clinical trials?
- ?Is the comprehensive multi-pathway improvement driven primarily by mitochondrial protection, or does SS-31 have additional non-mitochondrial effects?
- ?Could SS-31 be combined with existing PAH medications for additive benefit?
Trust & Context
- Key Stat:
- 8+ pathways improved SS-31 simultaneously improved oxidative stress, inflammation, calcium overload, apoptosis, fibrosis, hypoxia, DNA damage, and endothelial function in pulmonary hypertension
- Evidence Grade:
- This is a preclinical mouse model study with comprehensive biochemical and histological analysis. The breadth of markers examined strengthens the findings, but translation to human PAH requires clinical trials.
- Study Age:
- Published in 2016, this study contributed to the body of evidence supporting SS-31 (elamipretide) as a mitochondrial therapeutic. The peptide has since advanced through various stages of clinical development for other cardiovascular indications.
- Original Title:
- Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.
- Published In:
- Acta pharmacologica Sinica, 37(5), 589-603 (2016)
- Authors:
- Lu, Hung-I, Huang, Tien-Hung, Sung, Pei-Hsun, Chen, Yung-Lung, Chua, Sarah, Chai, Han-Yan, Chung, Sheng-Ying, Liu, Chu-Feng, Sun, Cheuk-Kwan, Chang, Hsueh-Wen, Zhen, Yen-Yi, Lee, Fan-Yen, Yip, Hon-Kan
- Database ID:
- RPEP-03028
Evidence Hierarchy
Frequently Asked Questions
What is SS-31 and how does it target mitochondria?
SS-31 (also called elamipretide or Bendavia) is a small four-amino-acid peptide that has a unique ability to selectively concentrate on the inner mitochondrial membrane. It stabilizes a key lipid called cardiolipin, which is essential for mitochondrial energy production and preventing oxidative damage. By protecting mitochondria from the inside, SS-31 prevents the cascade of damage that leads to cell injury and disease.
What is pulmonary arterial hypertension?
Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries that supply the lungs. The blood vessel walls thicken and stiffen, forcing the right side of the heart to work much harder. Over time, this can lead to right heart failure. Current treatments mainly work by dilating blood vessels but don’t address the underlying cell damage — which is why a mitochondria-protecting approach like SS-31 is potentially transformative.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03028APA
Lu, Hung-I; Huang, Tien-Hung; Sung, Pei-Hsun; Chen, Yung-Lung; Chua, Sarah; Chai, Han-Yan; Chung, Sheng-Ying; Liu, Chu-Feng; Sun, Cheuk-Kwan; Chang, Hsueh-Wen; Zhen, Yen-Yi; Lee, Fan-Yen; Yip, Hon-Kan. (2016). Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.. Acta pharmacologica Sinica, 37(5), 589-603. https://doi.org/10.1038/aps.2015.162
MLA
Lu, Hung-I, et al. "Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.." Acta pharmacologica Sinica, 2016. https://doi.org/10.1038/aps.2015.162
RethinkPeptides
RethinkPeptides Research Database. "Administration of antioxidant peptide SS-31 attenuates trans..." RPEP-03028. Retrieved from https://rethinkpeptides.com/research/lu-2016-administration-of-antioxidant-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.